# Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

> **NCT04408313** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Friends Research Institute, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Opioid-use Disorder

## Interventions

- **DRUG:** XR-B
- **DRUG:** XR-NTX

## Key facts

- **NCT ID:** NCT04408313
- **Lead sponsor:** Friends Research Institute, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-28
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-05-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04408313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04408313, "Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04408313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*